Published in Curr Opin Lipidol on August 01, 2011
Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy. J Lipid Res (2012) 0.83
Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice. J Lipid Res (2014) 0.78
Genetic analysis of intracapillary glomerular lipoprotein deposits in aging mice. PLoS One (2014) 0.76
A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy. Clin Exp Nephrol (2013) 0.76
Lipoprotein glomerulopathy associated with a mutation in apolipoprotein e. Clin Med Insights Case Rep (2013) 0.75
A review of drug-induced hyponatremia. Am J Kidney Dis (2008) 2.97
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation (2004) 1.91
Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant (2006) 1.90
Association of Helicobacter pylori infection with cardiovascular disease--is it just a myth? Eur J Intern Med (2010) 1.67
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin (2010) 1.56
Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med (2002) 1.49
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem (2005) 1.40
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
A review of drug-induced hypocalcemia. J Bone Miner Metab (2009) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
Apolipoprotein E and renal disease. Am J Kidney Dis (2004) 1.20
Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med (2011) 1.14
LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis (2006) 1.12
Prediabetes: to treat or not to treat? Eur J Pharmacol (2011) 1.11
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J (2011) 1.06
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol (2007) 1.05
Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP (2003) 1.04
Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism (2006) 1.02
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther (2007) 1.01
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol (2011) 1.00
Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res (2002) 1.00
Early vascular benefits of statin therapy. Curr Med Res Opin (2003) 0.99
Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. Ann Clin Lab Sci (2002) 0.98
Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin (2004) 0.97
Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol (2007) 0.97
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin (2007) 0.96
Influence of smoking on predictors of vascular disease. Angiology (2003) 0.96
Clinical and laboratory characteristics of hypernatraemia in an internal medicine clinic. Nephrol Dial Transplant (2007) 0.96
Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids (2007) 0.94
Benchmarking is associated with improved quality of care in type 2 diabetes: the OPTIMISE randomized, controlled trial. Diabetes Care (2013) 0.93
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol (2002) 0.93
Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology (2005) 0.93
Pharmacologically-induced metabolic acidosis: a review. Drug Saf (2010) 0.92
Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum (2008) 0.92
Native valve endocarditis due to Micrococcus luteus: a case report and review of the literature. J Med Case Rep (2011) 0.91
Hyponatremia in patients with infectious diseases. J Infect (2011) 0.91
Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis (2005) 0.91
The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids (2006) 0.91
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol (2011) 0.90
The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. Arch Med Sci (2012) 0.89
Persistent erythema multiforme in a patient with extrahepatic cholangiocarcinoma. Oncology (2008) 0.89
Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. Eur J Prev Cardiol (2012) 0.89
Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin (2003) 0.89
Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res (2009) 0.89
Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? Atherosclerosis (2009) 0.89
Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin (2004) 0.88
Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study. Atherosclerosis (2008) 0.88
The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther (2003) 0.87
Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res (2003) 0.87
Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J Cardiovasc Pharmacol Ther (2006) 0.87
Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism (2005) 0.87
Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. Cardiovasc Diabetol (2011) 0.86
Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol (2010) 0.86
Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids (2005) 0.86
Increased serum ferritin concentrations and liver enzyme activities in patients with metabolic syndrome. Metab Syndr Relat Disord (2006) 0.84
Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. J Cardiovasc Pharmacol Ther (2013) 0.84
Endocrine disorders: causes of hyponatremia not to neglect. Ann Med (2010) 0.84
Alarming atrioventricular block and mitral valve prolapse in the Kearns-Sayre syndrome. Int J Cardiol (2002) 0.84
Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant (2007) 0.84
Diverging trends in cardiovascular morbidity and mortality in a low risk population. Eur J Epidemiol (2009) 0.84
No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. Drug Metabol Personal Ther (2015) 0.84
How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr Med Res Opin (2014) 0.84
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens (2002) 0.83
Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. Lipids (2011) 0.83
Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. J Cardiovasc Pharmacol Ther (2012) 0.83
Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. Angiology (2011) 0.83
Successful treatment of human immunodeficiency virus-related Castleman's disease: a case report and literature review. Oncology (2003) 0.83
LDL-cholesterol calculation formulas in patients with or without the metabolic syndrome. Int J Cardiol (2006) 0.83
Hypokalemia due to Fanconi syndrome in a patient with obstructive jaundice. Nephron (2002) 0.83
The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin Ther Targets (2007) 0.83
Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia. J Lipid Res (2006) 0.82
The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study. Metabolism (2011) 0.82
Hypouricaemia as a marker of a generalized proximal tubular damage in alcoholic patients. Alcohol Alcohol (2002) 0.82
Factors associated with depression and anxiety of hospitalized patients with heart failure. Hellenic J Cardiol (2015) 0.82
Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J (2007) 0.82
Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. Curr Drug Targets (2007) 0.82
Effect of synthetic peptides corresponding to residues 313-332 of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3. Eur J Biochem (2004) 0.82
Autoimmune manifestations in patients with visceral leishmaniasis. J Microbiol Immunol Infect (2012) 0.81
The epsilon 2 and 4 alleles of apolipoprotein E and ischemic vascular events in the Greek population--implications for the interpretation of similar studies. Angiology (2003) 0.81
Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet Genomics (2005) 0.81
Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther (2002) 0.81
Causes and mechanisms of acid-base and electrolyte abnormalities in cancer patients. Eur J Intern Med (2007) 0.81
Salicylate-induced proximal tubular dysfunction. Am J Kidney Dis (2007) 0.80
Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology (2002) 0.80
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 0.80
Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis (2004) 0.79
Endothelial dysfunction, but not structural atherosclerosis, is evident early in children with heterozygous familial hypercholesterolemia. Pediatr Cardiol (2013) 0.79
Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. Open Cardiovasc Med J (2007) 0.79
Spurious electrolyte disorders: a diagnostic challenge for clinicians. Am J Nephrol (2013) 0.79
Electrolyte disturbances in patients with hyponatremia. Intern Med (2007) 0.79
Characterization of low density lipoprotein receptor (LDLR) gene mutations in Albania. Arch Med Sci (2010) 0.79
Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. Angiology (2009) 0.79